Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age

Lahey, J. Michael; Tunç, Murat; Kearney, John J.; Modlinski, Barbara; Koo, Howard; Johnson, Robert N.; Tanaka, Stephen

doi:10.1016/s0161-6420(01)00842-9

Cited by 138 publications

(89 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The role of lupus anticoagulant and anticardiolipin antibodies in RVO is uncertain [9,10,13,43,44,45,46,47,48,49,50,51]. The relationship between fibrinolysis and RVO has not received much attention, but so far does not show to be strong [10,15,16].…”

Section: Risk Factorsmentioning

confidence: 99%

Management of Retinal Vein Occlusion – Consensus Document

et al. 2011

View full text Add to dashboard Cite

Retinal vein occlusion (RVO) can have severe consequences for the people affected by the disease, including visual loss with costly social repercussions. Currently, there is no European consensus with regard to the management of RVO. Following a careful review of the medical literature as well as the data from several clinical trials, a collaborative group of retina specialists put forth practical recommendations based on the best available scientific evidence for the clinical approach to RVO. Taking into consideration the recent advances in diagnostic tools and management options, the present document aims to provide the European ophthalmologists with guidelines for clinical practice to the benefit of their patients.

show abstract

Section: Risk Factorsmentioning

confidence: 99%

Management of Retinal Vein Occlusion – Consensus Document

et al. 2011

View full text Add to dashboard Cite

show abstract

“…While an increasing number of systemic factors (especially those related to thrombophilia) 11,12 have been reported to be associated with CRVO in younger patients, the appropriate extent of systemic evaluation remains unclear. Conclusions regarding the advisability of systemic testing based on the current series should be drawn with caution, since testing of matched controls was not performed.…”

Section: Commentmentioning

confidence: 99%

Clinical Course of Younger Patients With Central Retinal Vein Occlusion

Recchia

Carvalho-Recchia²,

Hassan³

2004

Arch Ophthalmol

View full text Add to dashboard Cite

To describe the clinical course of patients 55 years and younger with central retinal vein occlusion (CRVO).Design and Methods: Retrospective, noncomparative case series. Medical records of 67 patients were reviewed for demographic, photographic, clinical, and visual acuity (VA) data. Data from 57 patients with at least 6 months of follow-up (mean, 29.2 months) were analyzed statistically.Main Outcome Measures: Best-corrected visual acuity and incidence of intraocular neovascularization.Results: Of 67 consecutive patients (55% men; mean age, 45 years), the median presenting VA was 20/50. Fortyfive patients (67%) were found to have at least 1 systemic disease. In 57 patients with at least 6 months of followup, the final VA was 20/40 or better in 42%, 20/50 to 20/ 100 in 18%, and 20/200 or worse in 40%. Visual decline was most common within 3 to 6 months of CRVO onset. Visual improvement was uncommon after 12 months. Of CLINICAL SCIENCES

show abstract

“…Higher levels of plasmatic homocysteine in patients with RVO have also been reported (34)(35) and two case-control studies identified MTHFR 677TT as a potential risk factor for RVO (32,36) . Nevertheless, most studies did not confirm the role of this mutation in RVO (26,(28)(29)(30) .…”

Section: Discussionmentioning

confidence: 86%